LONG-TERM VALUE FOR PATIENTS, SOCIETY AND INVESTORS
15
SCIENCE DRIVEN COMPANY WITH A FOCUSED MIND
BRINGING INNOVATION TO PATIENTS
Positioned for Sustainable Revenue Growth
Potential Wave 2 pipeline not included WAVE 1 PIPELINE*1 Vyvanse Velcade Azilva Hemophilia 14 GLOBAL BRANDS Others
WAVE 1 PIPELINE 14 GLOBAL BRANDS
Entyvio Others
PRO-FORMA REVENUE
2018
2024
2029
Note: The above chart represents conceptual changes in revenue through 2024 and 2029 demonstrating growth over time offsetting loss of exclusivities and achieving a single digit growth as compared to 2018 pro forma reven